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Background: Pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and
interleukin-6 (IL-6) play an important role in the development of hematopoietic stem cell transplantation (HSCT)
complications. We explored the effect of Selenium as an antioxidant and anti-inflammatory agent on pro-inflammatory
cytokines levels in HSCT candidates.
Findings: Plasma concentrations of TNF-α, IL-1β and IL-6 were measured in 74 patients from a double-blind,
randomized, placebo-controlled study. In both groups, there were 37 patients with median age of 32 years. Patients
received oral Se tablets (200 mcg) or placebo twice daily beginning from the first day of high dose chemotherapy
(HDC) through 14 days after HSCT. Cytokine levels were determined before starting HDC (prior to first dose of Se),
7 and 14 days after HSCT. Plasma levels of TNF-α were not significantly different between Se and control group
(P = 0.13). IL-1 levels were similar between two groups (P = 0.88). No significant differences were detected in IL-6 levels
between Se and control group (P = 0.96).
Conclusion: Selenium had no effect on pro-inflammatory cytokines levels in patients undergoing HSCT. It is likely that
earlier initiation and/or larger doses of Se are required to affect inflammatory cytokines significantly.
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Hematopoietic stem cell transplantation (HSCT) is one
of the most effective treatments for hematologic disor-
ders. It is applicable to many patients due to substantial
advances in the understanding of transplant immunology
as well as better supportive care [1]. Despite these im-
provements, transplant-related complications still remain
as major limitations of this curative modality. The serious
and potentially life-threatening complications include mu-
cositis, hepatic veno-occlusive disease, graft-versus-host
disease (GVHD) and infections [2]. It has been demons-
trated that pro-inflammatory cytokines including tumor* Correspondence: radfarma@tums.ac.ir
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unless otherwise stated.necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and
interleukin-6 (IL-6) play an important role in the develop-
ment of these complications [3-5].
High dose chemotherapy (HDC) prior to HSCT is one
of the main triggers of pro-inflammatory cytokines release.
Oxidative stress and reactive oxygen species (ROS), pro-
duced by the chemotherapeutic agents, are activators of a
number of transcription factors, such as nuclear factor-κB.
This factor is responsible for up-regulating the genes
which results in the production of pro-inflammatory cy-
tokines including TNF-α, IL-1β, and IL-6 [4,6]. Hence,
therapeutic agents which reduce oxidative stress or pro-
inflammatory cytokines levels could be suggested to
confront complications of HSCT. Previous studies have
confirmed significant positive effects of administrating
such agents including amifostine and TNF-α inhibi-
tors in prevention or amelioration of transplant-relatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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No. of patients 37 34
Baseline conc. (pg/ml) 2.02 ± 0.09 2.00 ± 0.10
+ 7 conc. (pg/ml) 1.98 ± 0.08 1.86 ± 0.08 0.13
+ 14 conc. (pg/ml) 2.18 ± 0.11 2.00 ± 0.11
IL-1β
No. of patients 32 28
Baseline conc. (pg/ml) 0.28 ± 0.01 0.29 ± 0.02
+ 7 conc. (pg/ml) 0.25 ± 0.01 0.25 ± 0.01 0.88
+ 14 conc. (pg/ml) 0.26 ± 0.01 0.26 ± 0.01
IL-6
No. of patients 34 29
Baseline conc. (pg/ml) 3.43 ± 0.67 2.83 ± 0.55
+ 7 conc. (pg/ml) 10.18 ± 0.67 9.77 ± 0.75 0.96
+ 14 conc. (pg/ml) 4.54 ± 0.72 4.73 ± 0.74
*Data are reported as mean ± SEM.
**Comparison of each cytokine levels on day +7 and +14 between Se and
control group.
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[7,8]. However based on our knowledge no similar study
was conducted to evaluate the effects of selenium (Se)
supplementation in HSCT setting.
Selenium, in the form of selenoproteines in particular
glutathione peroxidase (Glu.Px), is an essential com-
ponent of human cellular antioxidant defense system.
It also has anti-inflammatory effects by scavenging free
radicals [9].
We conducted a controlled study that indicated the ef-
ficacy of Se supplementation in reducing the incidence
of severe oral mucositis (WHO grade 3–4) in HSCT set-
ting [10]. In addition, significant improvements in serum
Se concentration and plasma Glu.Px activity in Se group
were revealed. In the present article, we report the ef-
fect of Se supplementation on plasma pro-inflammatory
cytokine (TNF-α, IL-1β and IL-6) levels in order to illus-
trate possible underlying mechanisms of observed clin-
ical outcomes.
The main study was a double-blind, randomized,
placebo-controlled clinical trial conducted from June
2011 to July 2012 in the Hematology–Oncology and
Stem Cell Transplantation Research Center (Dr. Shariati
Hospital), Tehran University of Medical Sciences, Tehran,
Iran. The study was registered in clinicaltrial.org (ID:
NCT01432873) and was approved by the institutional
ethics committee (ID: 900513) and written informed con-
sent was obtained from all patients before study entry.
Adult patients with diagnosis of AML or ALL, candi-
dates for allogeneic HSCT, were eligible for inclusion in
the study. The other criteria were Karnofsky performance
status >70% as well as adequate cardiac, pulmonary, renal
and hepatic function according to the institutional pro-
tocol. Eligible patients were randomly assigned to re-
ceive either Se tablets (Webber Naturals, Coquitlam, BC,
Canada, 200 mcg) or placebo using balanced blocked ran-
domization. The researchers, patients and clinical staff
were blinded to the randomization.
Patients received two tablets (either Se or placebo)
daily with 12 hours interval, beginning from the first day
of HDC through 14 days after HSCT. The HDC regimen
included busulfan 4 mg/kg/d orally in divided doses for
4 days followed by cyclophosphamide 60 mg/kg intra-
venously once daily for 2 days. One day after completion
of chemotherapy, patients received peripheral blood he-
matopoietic stem cell transplants from HLA-matched
sibling donors.
Blood samples were collected three times during each
patient’s hospital stay: before starting HDC (prior to first
dose of Se), 7 days (+7) and 14 days (+14) after HSCT.
Samples were collected in citrated tubes and centrifuged
for 10 min within 2 hours of sampling. Plasma was re-
moved and stored at −70˚C until assay. TNF-α, IL-1β, and
IL-6 plasma levels were determined using high sensitivityELISA kits (Bender Med, Vienna, Austria), following man-
ufacturer’s instructions.
Values are expressed as mean ± SEM. Changes in plas-
ma cytokines levels over time and as a function of group,
were analyzed by performing the repeated measures of
variance (ANOVA). P-value < 0.05 was considered as a
significant difference.
Seventy-seven patients entered the study. Among these,
3 patients discontinued and 74 patients completed the
study. Baseline characteristics of the patients were similar
in both study groups [10]. In each group there were
37 patients (16 females and 21 males) with median age of
32 years (ranged 18–55).
Results of cytokines measurements in both study groups
are summarized in Table 1. Due to some technical faults,
some of the samples were not available and the number of
analyzed samples varied for each cytokine. The mean
plasma levels of TNF-α, IL-1β, and IL-6 were not signifi-
cantly different between study groups at any sampling
time point. The pattern of change in the cytokines levels
was similar between two groups as well (there was no sig-
nificant group-time interaction). TNF-α level declined
slightly (P = 0.14) from baseline to day +7 and increased
significantly within the next 7 days (P = 0.03) in the en-
tire patient group. IL-1β level significantly decreased
from baseline to day +7 (P < 0.001) and increased within
the next 7 days (P = 0.89). Unlike the above cytokines,
IL-6 level significantly increased from baseline to day +7
Daeian et al. DARU Journal of Pharmaceutical Sciences 2014, 22:51 Page 3 of 4
http://www.darujps.com/content/22/1/51(P < 0.001) and dropped dramatically during the next
7 days (P < 0.001).
Results of our current study confirmed the changes in
pro-inflammatory cytokines levels after HSCT. The sig-
nificant increase in IL-6 level within few days after trans-
plantation, which was detected in all our study subjects,
was also reported by Wang et al. [11] and Melenhorst
et al. [12]. The slight decrease in TNF-α level during the
first week of transplantation and the subsequent eleva-
tion in its level, were demonstrated in Min et al.’s study
as well [13]. In addition, the pattern of change in IL-1β
level was similar to TNF-α, a finding that is consistent
with Melenhorst et al. [12] study.
On the other hand, despite a significant increase in
serum Se concentration and Glu.Px activity in Se group,
which we have reported previously [10], no significant
differences in cytokines levels were observed between
two groups at either time points. Two possible reasons
could be suggested to justify our findings. According to
our previous report, Se level and Glu.Px activity were
not significantly different between study groups until the
third week of Se supplementation. This implies that
while ROS and pro-inflammatory cytokines were gen-
erating during HDC, Glu.Px activity in Se group was
not significantly different with the control group. This
finding probably explains why the improvement in anti-
oxidative status of patients receiving Se did not alter the
pro-inflammatory cytokines levels in comparison with the
control group. Hence, earlier initiation or larger doses of
Se might be required to detect the anti-inflammatory ef-
fects of Se. In addition, based on Fall-Dickson et al.
study [14], local expression of pro-inflammatory cyto-
kines might be a more accurate marker for evaluating
anti-inflammatory effects of Se. In that study, TNF-α
concentration in plasma, saliva, and buccal epithelial cells
was measured at baseline and 9 days after conditioning
chemotherapy in HSCT patients. Significant differences in
the cytokine concentrations on day 9 were found between
the three samples. Evaluating oral pain at the same time
point, they suggested that the local level of TNF-α is a
more reliable indicator of oral mucositis severity. There-
fore, in our study, it is likely that Se supplementation re-
sulted in alteration of cytokines levels in local tissue rather
than peripheral blood.
Based on our results, inflammatory status of the pa-
tients in Se group did not improve; however they did
benefit from Se supplementation. Fischer et al. [15] have
defined a role for Se in the repair of the cells’ DNA
after their exposure to radiation or chemotherapy drugs.
Selenium exerts this function through a p53-dependent
pathway which is absent in tumor cells due to lack of
wild-type p53. They suggested this selective chemo-
protection as a mechanism to alleviate toxicities induced by
anti-cancer treatments especially DNA-damaging agents.Following administration of these agents, gut epithelium
and bone marrow are highly susceptible to DNA damage
due to their rapid proliferation. In our study all the subjects
received HDC consisted of busulfan and cyclophospha-
mide, both of which are DNA-damaging chemotherapeu-
tics. In agreement with the results of Fischer et al. [15]
study, following administration of Se, significant reduction
in the severity of mucositis as well as a marginally signifi-
cant decrease in duration of neutropenia was observed in
our study.
In summary, results of the current study suggests that
Se supplementation can prevent severe OM in HSCT
setting by mechanisms other than reducing production
of pro-inflammatory cytokines; however samples from
local tissues are also required to confirm our results. We
also hypothesize that earlier administration and/or using
larger doses of Se would result in optimum desired ef-
fects of Se supplementation in this setting. On the other
hand, the observed results could be due to the small sam-
ple size of the study as well. Larger randomized controlled
trials are recommended to evaluate these concepts.
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